Lower urinary tract symptoms · 2026
Autologous Transobturator Fascia Lata Sling for Female Stress Urinary Incontinence: A Pilot Feasibility and Safety Study.
Clinical StudyСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Salman Mohamed Fawzy Abdelfattah, Hassan Atef A, Wasfy Isaac Samir, Deif Hazem, Hassan Abdelrahman A, Hindawy Mohamed A, Hassan Abdalla Mohamed Abdalla, Ali Mohamed M, Abdel-Al Ibrahim, Koritenah Ayman K, Abuelazayem Tarek M, Keritna Hassan Kotb Mohamed
Аннотация
OBJECTIVE: To evaluate the preliminary safety, feasibility, and short-term outcomes of the autologous transobturator fascia lata sling for female SUI to our knowledge the first series using fascia lata via a transobturator route, in view of the mesh-related complications of synthetic midurethral slings and the limitations of rectus fascia harvest in women with prior abdominal surgery, central obesity, or scarred fascia.
METHODS: Prospective single-arm pilot feasibility and safety study of 40 women with SUI or stress-predominant mixed urinary incontinence (MUI) who underwent autologous transobturator fascia lata sling at Al-Azhar University Hospitals (June 2023 to May 2025; NCT05646745). Outcomes were assessed at 24 h, 2 weeks, and 3 months using the cough stress test, ICIQ-FLUTS questionnaire, and VAS pain scores.
RESULTS: Mean age was 48.9 ± 7.8 years; BMI 31.4 ± 4.1 kg/m2. At 3 months, the overall success rate (cured + improved) was 87.5%, and the objective cure rate (negative cough stress test) was 72.5%. ICIQ-FLUTS incontinence score decreased from 12.75 ± 3.41 to 3.23 ± 2.91 (p < 0.001, Cohen's d = 2.79); incontinence QOL from 35.88 ± 5.83 to 4.50 ± 7.22 (p < 0.001, d = 5.38). No voiding dysfunction, sling erosion, or major complications occurred. Grade I incontinence achieved 100% success. Thigh and groin pain resolved by 3 months in 92.5% and 100%, respectively.
CONCLUSION: This preliminary exploratory study suggests that autologous transobturator fascia lata sling is a feasible and promising mesh-free technique for female SUI with favorable short-term outcomes at 3 months. These results must be interpreted cautiously given the small sample size, short follow-up, and absence of a control group. Longer follow-up, multicenter validation, and randomized comparative studies are warranted.
TRIAL REGISTRATION: ClinicalTrials.gov: NCT05646745.
METHODS: Prospective single-arm pilot feasibility and safety study of 40 women with SUI or stress-predominant mixed urinary incontinence (MUI) who underwent autologous transobturator fascia lata sling at Al-Azhar University Hospitals (June 2023 to May 2025; NCT05646745). Outcomes were assessed at 24 h, 2 weeks, and 3 months using the cough stress test, ICIQ-FLUTS questionnaire, and VAS pain scores.
RESULTS: Mean age was 48.9 ± 7.8 years; BMI 31.4 ± 4.1 kg/m2. At 3 months, the overall success rate (cured + improved) was 87.5%, and the objective cure rate (negative cough stress test) was 72.5%. ICIQ-FLUTS incontinence score decreased from 12.75 ± 3.41 to 3.23 ± 2.91 (p < 0.001, Cohen's d = 2.79); incontinence QOL from 35.88 ± 5.83 to 4.50 ± 7.22 (p < 0.001, d = 5.38). No voiding dysfunction, sling erosion, or major complications occurred. Grade I incontinence achieved 100% success. Thigh and groin pain resolved by 3 months in 92.5% and 100%, respectively.
CONCLUSION: This preliminary exploratory study suggests that autologous transobturator fascia lata sling is a feasible and promising mesh-free technique for female SUI with favorable short-term outcomes at 3 months. These results must be interpreted cautiously given the small sample size, short follow-up, and absence of a control group. Longer follow-up, multicenter validation, and randomized comparative studies are warranted.
TRIAL REGISTRATION: ClinicalTrials.gov: NCT05646745.